Drugs / Emricasan
Emricasan
English name emricasan
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02121860 | Apr → Jul 2014 | liver disorder | Conatus Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02039817 | Jan → Apr 2014 | impaired renal function disease | Conatus Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01653899 | Jun 2012 → Jun 2016 | diabetes mellitus | University of Alberta | Completed | No outcome recorded |
| Phase 26 trials · 1 met primary · 2 missed | ||||||
| Phase 2 | NCT02230683 | Aug 2014 → May 2015 | cirrhosis of liver, portal hypertension | Conatus Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02230670 | Aug 2014 → Jan 2016 | cirrhosis of liver | Conatus Pharmaceuticals Inc. | Completed | Missed primary |
| Phase 2 | NCT02138253 | May 2014 → Feb 2018 | cirrhosis of liver, fibrotic liver disease | Conatus Pharmaceuticals Inc. | Completed | Missed primary |
| Phase 2 | NCT02077374 | Mar 2014 → Mar 2015 | NAFLD1, metabolic dysfunction-associated steatohepatitis | Conatus Pharmaceuticals Inc. | Completed | Met primary |
| Phase 2 | NCT01937130 | Sep 2013 → Jan 2015 | acute liver failure, alcoholic hepatitis, cirrhosis of liver | Conatus Pharmaceuticals Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT01912404 | Jul 2013 → Aug 2015 | alcoholic hepatitis | Conatus Pharmaceuticals Inc. | Terminated | No outcome recorded |
| Phase not stated2 trials | ||||||
| — | NCT03462576 | Jun 2017 → Jul 2019 | cirrhosis of liver | Meridian Bioscience, Inc. | Terminated | No outcome recorded |
| — | NCT03439189 | Aug 2016 → Apr 2019 | cirrhosis of liver, metabolic dysfunction-associated steatohepatitis, portal hypertension | Meridian Bioscience, Inc. | Completed | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 1 | NCT04803227 Comparator | Mar → May 2021 | COVID-19 | Histogen | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03205345 Comparator | Jun 2017 → Aug 2019 | cirrhosis of liver | Conatus Pharmaceuticals Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT02960204 Comparator | Oct 2016 → Oct 2018 | cirrhosis of liver, metabolic dysfunction-associated steatohepatitis, portal hypertension | Histogen | Completed | No outcome recorded |
| Phase 2 | NCT02686762 Comparator | Jan 2016 → Jan 2019 | metabolic dysfunction-associated steatohepatitis | Conatus Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00088140 Comparator | Jul 2004 → Oct 2005 | chronic hepatitis C virus infection | Conatus Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00080236 Comparator | Nov 2003 → Jan 2006 | cholestasis, hepatitis, hepatocellular carcinoma | Conatus Pharmaceuticals Inc. | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | emricasan | “taking a study drug called emricasan (also known as IDN-6556 and PF-03491390)” NCT01912404 ↗ |
| Known as | EMR | “Emricasan (EMR) is a pan caspase inhibitor.” NCT04803227 ↗ |
| Known as | IDN-6556 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01912404 ↗ |
| Known as | PF-03491390 | “taking a study drug called emricasan (also known as IDN-6556 and PF-03491390)” NCT01912404 ↗ |
| Known as | VAY-785 | ChEMBL registry synonym — accepted as the source's own label CHEMBL197672 ↗ |
| Action | Inhibit | “caspase inhibitor” NCT01653899 ↗ |
| Modality | Small molecule | — CHEMBL197672 ↗ |
| Route | Oral | “when given orally” NCT00088140 ↗ |